Katherine Fuh, MD, PhD

Associate Professor

Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms.

Wednesday, August 6th, 2025

Rethinking ovarian cancer III: the past decade and future directions.

Monday, April 13th, 2026

Correction: GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.

Tuesday, March 3rd, 2026

Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.

Wednesday, February 18th, 2026

Considering homologous recombination deficiency status in HIPEC: could molecular testing someday drive "targeted" surgery?

Monday, December 8th, 2025

See all their publications

September 19, 2019 - August 31, 2024 - Role of the microenvironment in ovarian cancer metastasis , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA234553